Research programme: autoimmune disorder therapeutics

Drug Profile

Research programme: autoimmune disorder therapeutics

Alternative Names: AI-001

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer BirchBioMed
  • Class Cell therapies; Hydroxyquinolines; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia; Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 25 Aug 2016 BirchBioMed in-licenses kynurenic acid and AI 001 from University of British Columbia before June 2016
  • 28 Aug 2015 Preclinical trials in Alopecia in Canada (unspecified route)
  • 28 Aug 2015 Preclinical trials in Psoriasis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top